Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva zahraničních věcí,

kterým xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. m. x. x č. 46/2008 Sb. m. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 1. xxxxx 2017 xxxx generální xxxxxxxxxx XXXXXX oznámeno schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X novým xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx vstoupilo xxxx xxxxx Xxxxxxx I x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx nového xxxxx Xxxxxxx X x xxxxxxxx přestalo xxxxxx xxxxx Přílohy X xxxxxx xx 1. xxxxx 2017 a xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx xxxxxx xxxxx Xxxxxxx I x xxxx překlad xx xxxxxxx xxxxxx xx xxxxxxxxx současně.

SVĚTOVÁ

ANTIDOPINGOVÁ

AGENTURA

SVĚTOVÝ ANTIDOPINGOVÝ XXXXX

XXXXXX XXXXXXXXXX LÁTEK X METOD XXXXXXX XXX ROK 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Seznamu xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X případě jakýchkoliv xxxxxxxxx xxxx xxxxxxxxx x francouzskou verzí xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

XXXXXX ZAKÁZANÝCH XXXXX A XXXXX XXXXXXX XXX XXX 2018

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. ledna 2018

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx za "Specifické xxxxx" kromě látek xx xxxxxx X1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx metod M1, X2 a X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (např. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* AAS, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-diol);

bolasteron;

danazol ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Endogenní** XXX, xxxxx xxxx xxxxxx exogenně:

Androstanolon (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx xxxxxxxxxx x xxxxxxx, včetně, xxx xx x omezením xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol; xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (SARM, xxxx. xxxxxxx, XXX-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx na xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx neprodukuje. ** "xxxxxxxxx " se xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx produkuje.

S2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ FAKTORY, XXXXXXXX LÁTKY X XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (EPO) x xxxxxxxxxx xxxxxxxxxxx erytropoézu, xxxxxx, xxx xx x omezením xxxxx xx xx:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX (XXX-Xx, methoxypolyethylenglykol-epoetin xxxx (CERA)); EPO-mimetické xxxxxxxxxx a jejich xxxxxxxxxx (xxxx. XXXX 530 a xxxxxxxxxxx).

1.2 Xxxxxxxxx prostředky xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (FG-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, např.

K-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného xxxxxxxxx xxxxxxxxx. xxxx.

xxxxxx XXX; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Choriogonadotropin (XX) x luteinizační xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxx, deslorelin, gonadorelin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx, x xxxx.

2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Růstový xxxxxx (GH), xxxx xxxxxxxxx x xxxxxxxxxx xxxxxxx, včetně, xxx xx s xxxxxxxx xxxxx xx ně:

fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176-191; xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x jeho analoga, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx hormonu (XXX), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, ipamorelin x xxxxxxxxxxx; xxxxxxxxxx peptidy xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5, GHRP-6 x hexarelin.

3. Xxxxxxx xxxxxxx x modulátory xxxxxxxxx xxxxxxx, xxxxxx, xxx xx s xxxxxxxx pouze na xx:

xxxxxxxxxxxxx růstové xxxxxxx (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx podobný růstový xxxxxx-1 (XXX-1) a xxxx xxxxxxx

xxxxxxxxxx růstové xxxxxxx (MGF);

růstový faktor xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x jeho xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF).

Další xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx faktorů xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx svalových xxxxxx.

X3. XXXX2- AGONISTÉ

Všichni xxxxxxxxxx i neselektivní xxxx-2 agonisté, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx zakázáni.

Zahrnují (xxx xx s omezením xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; terbutalin; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, nepřekračujících 800 xxxxxxxxxx během xxxxxxx 12 hodin xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx formoterolu x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx nebude xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx použití, ale xxxx považována xx xxxxxxxxx laboratorní nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou studií, xx xxxxxxxxxx výsledek xxx způsoben xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, než xxxx xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x metabolické xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

3. Xxxxxxx antiestrogenní xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, xxx xx s xxxxxxxx xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; a Agonisté Xxxxxxxxx xxxxx aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, GW501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 trimetazidin.

S5. XXXXXXXXX X MASKOVACÍ XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx látky jsou xxxxxxxx, xxxxxx xxxx xxxxx xxxxx s xxxxxxxx chemickou xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (např. xxxxxxxxxx podání albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); probenecid, ale xx s xxxxxxxx xxxxx na xx.

• Xxxxxxxxxxxx; xxxxxxxx; bumetanid; xxxxxxxxx; xxxxxxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid); xxxxxxxxxx a xxxxxxx (xxxx. xxxxxxxxx), ale xx x omezením xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamidu x brinzolamidu)

• Lokálního podání xxxxxxxxxxxx xxx zubní xxxxxxxxx

Xxxxx jakéhokoliv množství xxxxx se stanoveným xxxxxxxx limitem (tj. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx kdykoliv nebo xxxxxxxx Při Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx látku xxxxx x té, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx xxxxxxxxx krvinek x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx oběhového systému.

2. Xxxxx zvyšování xxxxxxxx, xxxxxxx nebo dodávky xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx xx ně. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými způsoby.

M2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, nebo Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx integritu x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx úpravu (xxxx. xxxxxxxxxx) xxxx, xxx ne s xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx celkem 100 xx xx 12 xxxxx kromě xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx zákroků, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

1. Použití xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx k transkripční xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk;

LÁTKY X XXXXXX ZAKÁZANÉ PŘI XXXXXXX

Xxxxx kategorií S0 xx X5 a X1 xx X3 xxxxxxxxx xxxx

xxxx Při Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx jejich případných xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx zakázaná.

Stimulancia xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia.

Zahrnují (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon x xxxx xxxxxxx (xxxx. xxxxxxxx, methedron x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (metylhexanamin);

niketamid;

norfenefrin;

oktopamin;

oxilofrin (metylsynefrin);

pemolin;

pentetrazol;

propylhexedrin;

pseudoefedrin*****;

selegilin;

sibutramin;

strychnin;

tenamfetamin (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx použití x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx rok 2018*.

* Xxxxxxxxx, fenylefrin, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x synefrin: Tyto xxxxx jsou zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2018 x nejsou xxxxxxxxxx za Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx v 1 xx moči.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx zakázány xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx aplikace xxxx xxxx xxxxxx xxxxxxxx x lokálními anestetiky.

***** Xxxxxxxxxxxxx: je xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx než 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující kanabinoidy xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. xxxxx, xxxxxx x marihuana.

• Syntetické kanabinoidy, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx orálně, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxx, xxx ne x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ X&xxxx;XXXXXXXX XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, x xxx xx to xxxxxxxx x Mimo xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (všechny xxxxxxxxxx) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x U-rampa, x xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx potápění) (XXXX) x disciplínách xxxxxxxxxx xxxx x ploutvemi xxxx xxx xxxxxxx, xxxxxxxxx apnoe x xxxxxxxxx xxxx xxx xxxxxxx, free xxxxxxxxx, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx na xxxx x variabilní xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx pouze xx xx.

Xxxxxxxxx

Xxxxxx předpis č. 36/2019 Sb. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Právní xxxxxxx x. 36/2019 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 32/2023 Sb. m. s. x účinností xx 22.8.2023.

Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného právního xxxxxxxx.

1) Xxxxxxxxxxx úmluva xxxxx dopingu ve xxxxxx, xxxxxxx dne 19. října 2005 x Xxxxxx, xxxx xxxxxxxxx v xxxxxxxxx xxxxx a s xxxxxxxxx do českého xxxxxx xxx č. 58/2007 Sb. m. s.

Nové xxxxx xxxxxxxx Úmluvy xx xxxxxxx jazyka xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.